Massachusetts Court Partially Sides with Teva in Ongoing Antitrust Inhaler Lawsuit

A significant development has unfolded in the ongoing legal battle involving Teva Pharmaceutical Industries Ltd., as a Massachusetts federal court decision partially favored the company. Although the court refused to dismiss the antitrust lawsuit accusing Teva of orchestrating a decade-long scheme to delay generic competition for its QVAR asthma inhalers, it has removed claims alleging Teva paid Amneal Pharmaceuticals Inc. to not launch a generic version of the inhaler. This decision highlights the complex legal dynamics in the pharmaceutical industry surrounding antitrust allegations and generic competition. For further details, visit the original article on Law360.